Losartan tab n / 50mg film about 30 pieces of ozone

$3.03

Losartan tab n / 50mg film about 30 pieces of ozone

5 in stock

Quantity:

Description

Composition
Active substance:
1 tablet contains: losartan potassium 12.5 mg, 50 mg or 100 mg.
Product form:
Tablets, film-coated 12.5 mg, 50.0 mg, 100.0 mg. 10, 30 tablets in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50, 60 or 100 tablets per plastic jars for medicaments. One jar or 1, 2, 3, 4, 5, 6 or 10, the contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
Contraindications
Increased sensitivity to the drug; severe liver failure (more than 9 points on the Child-Pugh); age of 18 years; lactose intolerance, lactase deficiency or glucose-galactose malabsorption; pregnancy and lactation.
Dosage
50 mg
Indications
Arterial hypertension. Chronic heart failure (in a combination therapy inefficiency or intolerance to treatment with ACE inhibitors). Reducing the risk of cardiovascular disease (including stroke) and mortality in patients with hypertension and left ventricular hypertrophy. Diabetic nephropathy and proteinuria or hypercreatininemia (ratio urine albumin and creatinine of more than 300 mg / day) in patients with type 2 diabetes and related hypertension (lowering of progression of diabetic nephropathy to terminal chronic renal failure).
pharmachologic effect
Pharmacological group:
Angiotensin II receptor antagonist. ATC code S09SA01.
Pharmacological properties:
Losartan is a specific antagonist of the angiotensin II receptor (subtype AT1) for oral administration. It suppresses kininazu II – an enzyme that catalyzes a reaction for conversion of angiotensin I to angiotensin II. Angiotensin II binds selectively to the AT1 receptor found in many tissues (smooth muscle tissues of blood vessels, adrenal glands, kidneys and the heart) and performs several important biological functions, including vasoconstriction and the release of aldosterone. Angiotensin II also stimulates the proliferation of smooth muscle cells. Losartan and its pharmacologically active metabolite (E 3174) both in vitro, in vivo and block all physiological effects of angiotensin II, regardless of the source or synthetic route. Losartan binds selectively to the AT1-receptor and does not bind to or block other hormone receptors and ion channels, which play an important role in the regulation of the cardiovascular system. Furthermore, losartan does not inhibit the angiotensin converting enzyme (ACE) – kininazu II, and, accordingly, does not prevent the destruction of bradykinin, however the side effects associated with the bradykinin indirectly (e.g., angioneurotic edema) occur infrequently. In applying losartan, no effect negative feedback on renin secretion leads to an increase in plasma renin activity. Increase renin activity leads to an increase in angiotensin II in the blood plasma. However, antihypertensive activity and reduced concentration of plasma aldosterone stored, which indicates the effective blockade of angiotensin II receptors. Losartan and its active metabolite exhibit a higher affinity for receptors of angiotensin I, angiotensin receptor than II. The active metabolite is 10-40 times more active than losartan. After a single oral antihypertensive effect (reduced systolic and diastolic blood pressure (BP)) reaches a maximum after 6 hours then for 24 hours gradually decreases. The maximum antihypertensive effect develops within 3-6 weeks after initiation of dosing. Patients with hypertension without concomitant diabetes with proteinuria (greater than 2 g / day), application of the drug significantly reduces proteinuria, urinary albumin and immunoglobulin G. It stabilizes the urea concentration in blood plasma. It has no effect on autonomic reflexes and has no long-term impact on the concentration of norepinephrine in the blood plasma. Losartan 150 mg per day did not affect the concentration of triglyceride, total cholesterol and high density lipoprotein (HDL) in the serum of patients with hypertension. The same dose of losartan is not affected by the concentration of glucose in blood on an empty stomach.
Conditions of supply of pharmacies
Prescription.
Dosing and Administration
Inside, regardless of the meal, the multiplicity of reception – 1 times per day. The tablets swallowed whole without chewing, washing down with water. When hypertension standard initial and maintenance dose for most patients is 50 mg 1 time / day. dose increased to a maximum daily dose of 100 mg 1 time per day in order to achieve greater therapeutic effect. The starting dose for patients with chronic heart failure is 12.5 mg 1 time per day. Typically, the dose is increased at weekly intervals (i.e., 12.5 mg / day, 25 mg / day and 50 mg / day) to an average maintenance dose of 50 mg 1 time per day, depending on patient tolerability of the drug. reducing the risk of cardiovascular disease (including stroke) and mortality in patients with hypertension and left ventricular hypertrophy – initial dose is 50 mg 1 time / day. Subsequently hydrochlorothiazide may be added in low doses or increased dose of Losartan preparation 100 mg of one or two steps in terms of reduction of blood pressure (BP). renal protection in patients with type 2 diabetes, and proteinuria – Losartan drug administered in an initial dose – 50 mg 1 time per day to a further increase in dose to 100 mg / day (given degree of reduction in blood pressure) in one or two steps. In patients with reduced BCC (e.g., diuretics in high doses) Losartan recommended initial dose of the drug is 25 mg 1 time / day. No need for the selection of the initial dose in patients with renal failure, including patients on dialysis. No need for dose selection in the elderly, although it is recommended to start treatment with a dose of 25 mg in patients over 75 years. Patients with a history of liver disease is recommended to assign the drug at lower doses. Application Losartan is contraindicated in patients with severe liver failure, since there is no clinical application of experience in these patients (see. The section “Contra ‘). Safety and efficacy in children under 18 years of age has not been established.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

OZONE generics

There are no reviews yet.

Add your review